List view / Grid view
16 August 2016 | By Janssen
Following succesful phase II trials, the FDA have granted a Breakthrough Therapy Designation for esketamine, an investigational antidepressant medication...
8 June 2016 | By Victoria White, Digital Content Producer
The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis...
1 June 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF).
25 May 2016 | By Victoria White, Digital Content Producer
Data shows that a greater proportion of adult patients with Crohn's disease receiving Stelara SC maintenance therapy were in clinical remission at one year...
25 May 2016 | By Victoria White, Digital Content Producer
NICE has published final guidance recommending three drugs for treating type 2 diabetes: canagliflozin, dapagliflozin and empagliflozin...
1 April 2016 | By Victoria White
Daratumumab combination treatment regimen improved progression-free survival compared with bortezomib and dexamethasone alone...
22 March 2016 | By Victoria White
The studies will assess the combination of daratumumab and atezolizumab in multiple myeloma and in solid tumour cancer...
21 March 2016 | By Victoria White
Professor Paul Workman of The Institute of Cancer Research, which discovered abiraterone, said the recommendation was “a big victory for men"...
11 November 2015 | By Victoria White
HM12525A is a novel biologic GLP-1/Glucagon dual receptor agonist to treat diabetes and obesity...
26 May 2015 | By Victoria White
CHMP has adopted a positive opinion of Simponi for the treatment of adults with severe active non-radiographic axial spondyloarthritis...
9 December 2014 | By Janssen
International Health Partners (IHP) in partnership with Banco Farmaceutico and Action Medeor has launched EURMED; a unique industry collaboration that enables the donation of medicines for disaster relief and humanitarian aid.
26 November 2014 | By Janssen
Economic and societal value of Europe’s biopharmaceutical sector can only be sustained if risks to innovation are adequately rewarded, study concludes...
11 August 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration has approved INVOKAMET™, a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes...
26 June 2014 | By Janssen Pharmaceutica
New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide...
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
